[Combined laser therapy of the reactivated form of cytomegalovirus infection of the urogenital tract in the women of reproductive age].

The prevalence of cytomegalovirus infection (CMVI) dictates the necessity of its in-depth investigation in the patients presenting with the signs of chronic inflammatory diseases of sexual organs. The objective of the present study was to estimate the effectiveness of combined laser therapy of inflammatory diseases of the urogenital tract accompanied by the reactivation of CMVI concomitant with other infections. The examination of 158 women presenting with cytomegalovirus infection revealed clinical and laboratory characteristics of the microbiocenosis. These data may be used to improve the effectiveness of diagnostic and therapeutic strategies for such patients. The combined treatment of the patients with the reactivated form of CMVI using josamycin and doxycycline monohydrate in combination with panavir and low-intensity laser irradiation based at the "Matrix-Urolog" laser complex resulted in the favourable outcome of therapy in the majority of the patients.

[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension].

Efficacy and safety of the use of atorvastatin in complex treatment of extensive psoriasis was studied in 63 patients with psoriasis and arterial hypertension (AH). Complex clinical functional examination was carried out at study entry and after 6 months of treatment. Psoriasis severity was evaluated with PASI scale, quality of life with DLQI, PDI and SF 36 questionnaires. Degree of systemic inflammation (IL 10, TNF , hsCRP) and local (TNF , rc TNF , LFA 1) systemic immune inflammation was also assessed. Patients were randomized into either atorvastatin group (20 mg/day, n=48) or standard therapy group (n=15). Initially there was no significant difference between groups in psoriasis severity (PASI 22.2 [13.3; 24.6]) and 22.6 [19.3; 23.6], respectively). Six months of therapy with atorvastatin resulted in significant lowering of PASI (3.6 [1.6;4.8]) compared with 17.0 [15.0; 20.1] in control group, p0.01]); 47.9% of patients achieved PASI -50% in 3 weeks and 95.8% - after 6 months of therapy (0% and 13.3% in control group); 81.3% of patients achieved level of PASI -75% by 6th month of treatment. Positive dynamics of therapy was accompanied with significant improvement of quality of life according to data of PDI and DLQI. After 3 weeks of therapy significant lowering of TNF (from 1.45 [0.6; 1.8] to 1.0 [0.6; 1.4], p<0.05) and hs-CRP (from 5.4 [2.4; 7.1] to 3.3 [2.9; 5.5], p<0.05) took place in atorvastatin group. Antiinflammatory effect of atorvastatin persisted by month 6 (TNF 0.7 [0.4; 1.2] compared with 1.4 [1.3; 1.6] in control group, p0.05); hsCRP (3.1 [2.4; 5.0] 5.5 [2.2; 12.1]) in control group, p<0.05). Significant lowering of local immune inflammation was also occurred in atorvastatin group.Thus therapy with atorvastatin was effective and safe in patients with psoriasis and AH.

[Skin changes in diabetes mellitus]. / Kozhnye izmeneniia pri sakharnom diabete.

Basing on analysis of case histories of 264 diabetics, the authors have developed an original classification of the dermatoses occurring in diabetes mellitus. Clinical and laboratory findings evidence the identity of changes in the peripheral blood levels of calcium and immunoreactive insulin in the patients with psoriasis, neurodermatitis, and diabetes mellitus.